Share
1,230 Posts.
lightbulb Created with Sketch. 395
clock Created with Sketch.
28/05/19
22:53
Share
Originally posted by Red bar:
↑
Thank you. Yes and this is where the whole risk vs reward ratio comes into play - there will be a huge reward here IF our company can pull it off and deliver the goods... In a way the telehealth market for ResApp is like the Abbey pain scale measurement for PCK, telehealth consultations use visual features to determine their respiratory disease with an add on bonus to be able to verbally communicate with their patients and ask them what specific symptoms they're suffering from, obviously people like dementia sufferers or infants who are not verbally able to communicate can still use this feature with the aid of a loved one or friend. IMO in a way PCK's market is even covered here as ResApp could ultimately reduce pain and suffering brought on by the onset of an undiagnosed respiratory condition developing into something more serious leading to pain and suffering. Thankfully one does not need to be able to verbally communicate to inform that one is sick as the coughing signature has no part of one's vocal cords so therefore if resapp make it to market they could even target aged care facilities to help diagnose dementia sufferers from their respiratory disease that they may be suffering from. Correct there are gold standards within the medical sphere that we look up to and strive to exceed.. currently Australian results Point to accuracy levels of very high accuracy exceeding that of a doctor with a stethoscope who's diagnosis maybe subjective. Thankfully even in the US we also reached this target with 3 out of the 6 main respiratory ailments to be in the 70% range. Stethoscopes in some medical journals I have viewed have produced accuracy levels only in the mid 60's & low 70%. Some of these I have posted up on the threads here before... As far as I'm concerned RAP's efficiency is no longer in doubt the clinical trials speak volumes particularly the Australian results (used for CE regulatory approval) and the US results are good enough to get us over the line, yes the variants in the results were a question for me when initially published but once I realised what the issue was it became evident that our device is more accurate than what it seems. The subjective nature of doctor's diagnosis particularly in the United States shows that... There is room for reform, the future is Grim for the stethoscope IMO. Cheers Red bar
Expand
Yes, I do believe that our time in the sun is coming - and it's no longer a binary outcome for all that RAP offers, with sleep apnoea plus at least a good number of the respiratory diseases looking good for FDA. Re "the future is Grim for the stethoscope ", that reminds me of when I mentioned ResApp and the stethoscope comparisons to my GP a few years ago - he's a great bloke and best GP I ever had - but he looked at me and said - it's what's between the ears that counts, not the stethoscope itself" - but then, he is also very experienced - but this also illustrated to me that when clinicians are comfortable with what tools they use, how the rate of uptake outside of telehealth may not be as rapid as we would like - time will tell.